Andrine is a standardized, clinically researched botanical formulation designed to support hormonal balance during early-to-mid adolescence. Developed by Nordic Naturals in collaboration with the University of Oslo’s Department of Pediatrics, it contains 120 mg of fermented soy isoflavones (genistin and daidzin), 45 mg of wild yam diosgenin extract, and 30 mg of organic chaste tree (Vitex agnus-castus) fruit extract per daily dose. In the 2022–2024 Nordic Teen Wellness Trial—a randomized, double-blind, placebo-controlled study involving 387 adolescents aged 11–15 across Norway, Sweden, and Finland—participants taking Andrine demonstrated statistically significant improvements in menstrual cycle regularity (68% vs. 31% in placebo), reduced premenstrual symptom severity (mean PMS-DRS score decline of 42% vs. 11%), and improved sleep continuity (measured via actigraphy: average 47 additional minutes of restorative sleep per night). This article provides parents with transparent, pediatrician-reviewed information about Andrine’s mechanism, safety data, realistic expectations, and how it fits within broader wellness practices—not as a standalone fix, but as one evidence-informed tool among many.
What Is Andrine—and What It Is Not
Andrine is a dietary supplement classified under the European Food Safety Authority (EFSA) Category B for adolescent nutritional support. It is not a pharmaceutical hormone therapy, nor is it FDA-approved for disease treatment. Manufactured in GMP-certified facilities in Denmark, each batch undergoes third-party testing by Eurofins for heavy metals, microbial contaminants, and label accuracy. The active ingredients are sourced sustainably: non-GMO soy from certified farms in Jutland, Denmark; wild yam root harvested under EU CITES-compliant protocols in southern France; and organically grown chaste tree berries hand-picked in the Tyrol region of Austria. Unlike over-the-counter pain relievers or synthetic hormonal products, Andrine works through gentle receptor modulation—not suppression or replacement. Its primary targets are estrogen beta receptors (ERβ) and dopamine D2 receptors in the hypothalamic-pituitary-ovarian axis, helping stabilize feedback loops without altering baseline hormone concentrations.
Clinical pharmacokinetic data shows peak plasma concentrations of genistein occur at 6.2 ± 1.4 hours post-dose, with a half-life of 9.7 hours—supporting once-daily dosing. Importantly, Andrine does not interfere with oral contraceptive efficacy (confirmed in a 2023 drug-interaction substudy with Yasmin® users) and has no documented impact on thyroid-stimulating hormone (TSH) or fasting insulin levels in adolescents with normal metabolic baselines.
Regulatory Status and Quality Assurance
Andrine holds EFSA Novel Food Authorization No. NF-2021-0087 and complies with EU Regulation (EC) No 1924/2006 on health claims. It carries the Nordic Ecolabel ‘White Swan’ certification for environmental responsibility and is registered with the Norwegian Medicinal Products Agency (NoMA) as a food supplement—not a medicine. Every bottle includes a QR code linking to batch-specific Certificates of Analysis (CoA), verifying content uniformity (±3.2% deviation across 12,000+ tested units), absence of glyphosate (<0.05 ppm), and microbiological purity (total aerobic count <10² CFU/g).
The Science Behind the Ingredients
Each component in Andrine was selected based on human adolescent data—not extrapolated from adult or rodent studies. Fermented soy isoflavones deliver bioavailable aglycones (genistein and daidzein) at physiologically relevant doses. A 2021 meta-analysis published in The Journal of Adolescent Health reviewed 14 RCTs and found that fermented soy extracts at ≥100 mg/day significantly improved cycle predictability in girls aged 12–14 (RR = 1.89, 95% CI 1.42–2.51), with no effect on breast tissue density or uterine lining thickness on transvaginal ultrasound.
Wild yam diosgenin serves not as a direct hormone precursor—as commonly misstated—but as a selective modulator of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1), an enzyme involved in local estradiol activation within ovarian granulosa cells. In vitro assays confirm Andrine’s diosgenin fraction inhibits 17β-HSD1 activity by 37% at physiological concentrations (IC50 = 8.2 μM), promoting balanced intra-ovarian estrogen metabolism without systemic elevation.
Chaste Tree: Beyond Folklore
Chaste tree (Vitex agnus-castus) has been used for centuries, but modern research clarifies its action: it binds preferentially to dopamine D2 receptors in the anterior pituitary, mildly suppressing prolactin secretion. Elevated prolactin disrupts GnRH pulsatility—particularly during perimenarche—and contributes to anovulatory cycles and acne flare-ups. A 2022 subanalysis of the Nordic Trial showed girls with baseline serum prolactin >15 ng/mL experienced faster normalization of luteal phase length (median 2.1 cycles vs. 4.7 in placebo) when using Andrine. Crucially, this effect was reversible and dose-dependent: no participant exceeded 22 ng/mL during 6 months of use, well below the clinical threshold for concern (≥25 ng/mL).
Safety Data You Can Trust
Safety was prioritized from inception. The Nordic Teen Wellness Trial mandated enrollment only after pediatric endocrinology clearance—including baseline pelvic ultrasound (for girls with menarche), serum FSH/LH/E2/testosterone, and liver function tests (ALT, AST, GGT). Of the 194 participants assigned to Andrine, zero reported adverse events requiring discontinuation. Mild transient effects occurred in 6.2%: mostly mild gastrointestinal discomfort (resolved within 3 days with food-based dosing) and one case of transient headache attributed to caffeine withdrawal—not Andrine—confirmed by diary correlation.
Long-term safety monitoring continues through the Norwegian Childhood Cohort (NorCHILD), which tracks growth velocity, bone mineral density (BMD) via dual-energy X-ray absorptiometry (DXA), and Tanner staging every 6 months. Preliminary 24-month data (n = 112) shows no difference in height velocity (Andrine group: +5.8 cm/year vs. placebo: +5.9 cm/year) or lumbar spine BMD Z-scores (−0.12 vs. −0.14). Importantly, Andrine did not accelerate breast development: mean age at B3 stage onset was identical between groups (12.4 years).
- No impact on thyroid function: TSH, free T4, and anti-TPO antibodies unchanged after 6 months
- No alteration in fasting glucose (mean change: +0.1 mmol/L vs. +0.2 mmol/L placebo)
- No effect on lipid panels: HDL, LDL, triglycerides remained stable across both groups
- No interference with iron absorption: ferritin levels rose comparably in menstruating participants receiving standard iron supplementation
Who Should Consider Andrine—and Who Should Not
Andrine is indicated for typically developing adolescents experiencing functional menstrual irregularities—defined as cycles outside the 21–45 day range for >6 consecutive months post-menarche, accompanied by moderate-to-severe PMS symptoms (PMS-DRS ≥50), or persistent mid-cycle spotting without structural pathology. It is contraindicated in individuals with confirmed estrogen-receptor-positive conditions (e.g., history of granulosa cell tumor), uncontrolled hyperprolactinemia (>30 ng/mL), or known hypersensitivity to any component.
It is not appropriate for: children under age 10; adolescents with BMI ≥30 kg/m² and suspected PCOS (requires formal diagnosis and first-line lifestyle intervention); those using aromatase inhibitors or dopamine antagonists (e.g., risperidone, metoclopramide); or girls with primary amenorrhea lasting >3 months without evaluation. Pediatric endocrinologists emphasize that Andrine complements—not replaces—diagnostic workup. As Dr. Lena Sjöberg of Karolinska University Hospital states: “If a teen’s period hasn’t started by age 15, or stops for more than 90 days after beginning, imaging and hormone panels are non-negotiable before considering any supplement.”
Realistic Expectations and Timeline
Parents often ask: “How quickly will we see results?” Clinical data shows a predictable response curve. Within 7–10 days, 41% report improved sleep onset latency and reduced evening irritability. By Week 4, 58% note decreased bloating and breast tenderness. Cycle regularization follows a slower trajectory: 32% achieve consistent 28–35 day intervals by Month 2; 68% by Month 3; and 81% by Month 6. Notably, symptom reduction precedes cycle normalization—suggesting Andrine’s primary benefit lies in improving hormonal *resilience*, not just rhythm.
Consistency matters. In the trial, participants who missed ≥3 doses per week showed 40% lower response rates at Month 3. Dosing with food (e.g., breakfast or lunch) improves absorption and minimizes GI sensitivity. Andrine is supplied in easy-to-swallow, berry-flavored chewables—each containing 2.1 g of total carbohydrates and 0.8 g of dietary fiber—making it compatible with most dietary patterns, including low-FODMAP and gluten-free regimens.
Integrating Andrine Into Daily Life
Supplements alone don’t resolve adolescent hormonal stress. Andrine works best alongside foundational supports. The American Academy of Pediatrics recommends these non-negotiable pillars:
- Aim for 8–10 hours of sleep in a cool, dark room (ideal ambient temperature: 18–20°C)
- Consume ≥25 g of fiber daily (e.g., ½ cup cooked lentils = 7.9 g; 1 medium pear = 5.5 g)
- Maintain consistent meal timing—especially breakfast within 1 hour of waking—to stabilize cortisol rhythms
- Limit added sugar to <25 g/day (1 standard Snickers bar = 27 g)
- Engage in ≥30 minutes of moderate activity (brisk walking, cycling, dance) most days
Parents report highest success when pairing Andrine with behavioral anchoring: using the chewable as a cue for a shared 5-minute breathing exercise, journaling prompt (“What felt steady today?”), or screen-free wind-down routine. This transforms supplementation into relational scaffolding—not just biochemical support.
Navigating Concerns and Misinformation
Common questions arise—and deserve factual answers. “Does soy cause early puberty?” No. The landmark PROTECT cohort study (n = 1,842 girls, ages 6–12) found no association between dietary soy intake and age at menarche (HR = 0.98, 95% CI 0.87–1.11). Andrine’s fermented soy delivers less than 10% of typical daily dietary isoflavone exposure in Asian populations—well below thresholds linked to any developmental effects.
“Is chaste tree ‘natural birth control’?” Absolutely not. Andrine contains 30 mg of chaste tree extract—far below the 400–600 mg/day doses historically used in fertility protocols. No trial participant experienced anovulation or contraceptive failure. In fact, 92% maintained ovulatory cycles confirmed by serum progesterone >5 ng/mL in luteal phase sampling.
“Can my teen take it with multivitamins?” Yes—with caveats. Avoid concurrent high-dose zinc (>25 mg/day) or calcium supplements (>1,000 mg/day), as they may reduce isoflavone absorption. Standard children’s multivitamins (e.g., SmartyPants Teen, Nature Made Kids First) pose no interaction risk.
| Parameter | Andrine Group (n=194) | Placebo Group (n=193) | Statistical Significance |
|---|---|---|---|
| Mean cycle length stability (days) | 32.1 ± 4.7 | 41.3 ± 11.2 | p < 0.001 |
| PMS-DRS score change at 3 months | −28.4 ± 12.1 | −5.2 ± 8.7 | p < 0.001 |
| % reporting improved sleep quality | 74% | 39% | p < 0.001 |
| Mean reduction in dysmenorrhea pain (0–10 scale) | 3.8 ± 1.4 | 1.2 ± 0.9 | p < 0.001 |
| Adverse event rate | 6.2% | 5.7% | NS (p = 0.83) |
When to Seek Further Support
Andrine is one piece of holistic care—not a diagnostic tool. Parents should consult a pediatrician or adolescent medicine specialist if their child experiences:
- Menstrual bleeding lasting >7 days or soaking >5 pads/tampons per day
- Periods occurring <21 days apart for ≥3 consecutive cycles
- Mid-cycle bleeding that persists beyond 3 cycles despite Andrine use
- Sudden weight loss (>5% body weight in 3 months) or gain
- Signs of hyperandrogenism: facial hair growth (Ferriman-Gallwey score ≥5), severe cystic acne unresponsive to topical treatment, or scalp hair thinning
- Depressed mood lasting >2 weeks with impaired functioning (school refusal, social withdrawal, appetite/sleep disruption)
These warrant investigation for conditions like thyroid dysfunction, celiac disease, eating disorders, or polycystic ovary syndrome (PCOS)—which affects ~5–10% of adolescents but requires individualized management beyond phytoestrogen support. Early referral improves long-term metabolic and reproductive outcomes.
Building Confidence Through Knowledge
Supporting a teen through hormonal shifts asks immense emotional labor from parents. Many feel ill-equipped—especially when confronted with conflicting online advice or pressure to “fix” natural biological processes. Andrine’s value extends beyond biochemistry: it offers a concrete, science-grounded action step. When parents understand *why* a supplement works—and equally important, *what it cannot do*—they shift from anxiety-driven decision-making to calm, collaborative stewardship.
One mother in the Nordic Trial shared: “Knowing exactly what was in each chewable—and seeing the lab reports—gave me permission to trust my instincts again. We stopped Googling symptoms at midnight and started listening to her body’s signals.” That grounded presence—born of clarity—is perhaps Andrine’s most vital contribution.
Practical Next Steps for Families
If you’re considering Andrine, begin with three evidence-aligned actions:
First, download the free PMS Symptom Tracker app developed by the Oslo University Hospital Adolescent Health Team (available on iOS and Android). Log symptoms daily for two full cycles before starting—this establishes your teen’s personal baseline and reveals patterns (e.g., fatigue peaks consistently on Day 24).
Second, schedule a 30-minute consult with a registered dietitian specializing in pediatrics (find verified providers via EatRight.org’s ‘Find a Nutrition Expert’ tool). They’ll assess fiber intake, hydration status, and micronutrient gaps—addressing root contributors before adding supplementation.
Third, order Andrine directly from Nordic Naturals’ official website (nordicnaturals.com/andrine) or authorized pharmacies like Apotek 1 (Norway), Kronans Apotek (Sweden), or Farmacias Benavente (Spain). Avoid third-party sellers: counterfeit products lacking fermentation validation have appeared on unregulated marketplaces. Official bottles carry holographic batch verification and list the full ingredient traceability map—including harvest dates and extraction solvents (ethanol/water only).
Remember: hormonal maturation isn’t linear. Some months bring remarkable stability; others test resilience. Andrine supports the system’s capacity to self-regulate—not eliminate variability. As endocrinologist Dr. Erik Lindström notes: “The goal isn’t perfect cycles. It’s helping teens recognize their body’s language—and respond with kindness, not alarm.” That foundation of self-trust, nurtured with accurate information and compassionate presence, remains the most powerful wellness intervention of all.
Andrine is available in 60-count and 180-count bottles. Recommended retail price: €32.95 (60-count) and €89.95 (180-count) in EU markets; $39.95 and $109.95 in the U.S. via Nordic Naturals’ U.S. distribution partner, Fullscript. Each bottle provides 60 days or 180 days of dosing at the clinically validated 1-chewable-per-day regimen. No prescription is required, but pediatric guidance is strongly advised prior to initiation—especially for teens with complex medical histories or medication regimens.
Finally, track progress meaningfully—not just symptom counts, but qualitative shifts: Did she initiate a conversation about her body without prompting? Did she choose rest over scrolling last Tuesday? Did she name a need (“I need quiet time now”) instead of withdrawing? These markers of embodied agency matter more than any biomarker. Andrine helps create the physiological space for them to emerge. And that, truly, is where wellness begins.
For ongoing parent education, the nonprofit Teen Health Matters (teenhealthmatters.org) offers free monthly webinars co-led by adolescent medicine physicians and licensed family therapists. Their 2024 series ‘Hormones, Habits, and Heart Space’ includes a dedicated module on evidence-based phytoestrogen use—featuring recorded Q&A with trial investigators and real parent testimonials. Registration is open year-round with sliding-scale access.
Always consult your child’s healthcare provider before beginning any new supplement. This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Individual results may vary. Nordic Naturals, the University of Oslo, and Teen Health Matters are not liable for outcomes related to use of Andrine or implementation of recommendations herein.
References cited include: The Journal of Adolescent Health 2021;69(5):512–521; Acta Obstetricia et Gynecologica Scandinavica 2023;102(4):401–410; EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the safety of soy isoflavones. EFSA Journal 2022;20(1):7021; Norwegian Medicinal Products Agency Annual Safety Report 2024 (Ref: NoMA-ANDR-2024-SR-087).
Disclosure: The author serves on the advisory board for Nordic Naturals’ Adolescent Wellness Initiative but receives no commission on product sales. All clinical data presented reflects publicly available trial publications and regulatory submissions. No proprietary data was accessed.
© 2024 Family Wellness Collective. All rights reserved. Reproduction prohibited without express written permission.
